Published in Cancer Res on May 01, 1993
Ovarian cancer development and metastasis. Am J Pathol (2010) 5.92
Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol (2009) 3.90
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer (2008) 2.47
Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am J Pathol (2000) 1.35
p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer (1997) 1.21
MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary. PLoS One (2009) 1.18
The genetic analysis of ovarian cancer. Br J Cancer (1995) 1.16
Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53. Nucleic Acids Res (1994) 1.10
Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass. Br J Cancer (2000) 1.04
Expression of the zinc finger gene EVI-1 in ovarian and other cancers. Br J Cancer (1996) 1.01
Potential markers for detection and monitoring of ovarian cancer. J Oncol (2011) 1.01
Allelic analysis of serous ovarian carcinoma reveals two putative tumor suppressor loci at 18q22-q23 distal to SMAD4, SMAD2, and DCC. Am J Pathol (2001) 0.96
MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status. Br J Cancer (1995) 0.95
Loss of heterozygosity on chromosome 5q in ovarian cancer is frequently accompanied by TP53 mutation and identifies a tumour suppressor gene locus at 5q13.1-21. Br J Cancer (1996) 0.92
Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Pathol (1995) 0.92
Aberrant TGFβ/SMAD4 signaling contributes to epigenetic silencing of a putative tumor suppressor, RunX1T1 in ovarian cancer. Epigenetics (2011) 0.92
p53 is a persistent and predictive marker in advanced ovarian carcinomas: multivariate analysis including comparison with Ki67 immunoreactivity. J Cancer Res Clin Oncol (1997) 0.88
The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1. Mol Med (2011) 0.88
P53, bcl-2, ki-67 li (labeling index) status in benign, proliferative, and malignant ovarian surface epithelial neoplasms. Eurasian J Med (2009) 0.87
Epithelial ovarian cancer: the role of cell cycle genes in the different histotypes. Open Clin Cancer J (2008) 0.85
Is mucinous carcinoma of the colorectum a distinct genetic entity? Br J Cancer (1995) 0.83
Molecular genetic evidence for unifocal origin of advanced epithelial ovarian cancer and for minor clonal divergence. Br J Cancer (1995) 0.80
Allele loss from large regions of chromosome 17 is common only in certain histological subtypes of ovarian carcinomas. Br J Cancer (1996) 0.80
Absence of constitutive EGF receptor activation in ovarian cancer cell lines. Br J Cancer (1996) 0.77
Cancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy. BMC Cancer (2015) 0.75
Prognostic biomarkers in ovarian cancer. Cancer Biomark (2011) 0.75
Selective genetic analysis of p53 immunostain positive cells. Mol Pathol (2000) 0.75
The Prognostic Significance of the Serum p53 Protein Concentration in Chinese Patients with Non-Hodgkin Lymphoma. Turk J Haematol (2012) 0.75
p53 mutation is associated with high S-phase fraction in primary fallopian tube adenocarcinoma. Br J Cancer (1996) 0.75
Somatic mutations of the PPP2R1B candidate tumor suppressor gene at chromosome 11q23 are infrequent in ovarian carcinomas. Neoplasia (1999) 0.75
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67
One thousand heart attacks in Grampian: the place of cardiopulmonary resuscitation in general practice. Br Med J (Clin Res Ed) (1987) 6.93
Randomised trial of hysterectomy, endometrial laser ablation, and transcervical endometrial resection for dysfunctional uterine bleeding. BMJ (1994) 5.76
Patient and general practitioner delays in acute myocardial infarction. Br Med J (Clin Res Ed) (1988) 4.94
Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol (2001) 4.45
Invasive cervical cancer after conservative therapy for cervical intraepithelial neoplasia. Lancet (1997) 4.38
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer (2008) 3.87
Management of women with mild and moderate cervical dyskaryosis. BMJ (1994) 3.65
A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet (2004) 3.10
Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res (1988) 2.40
Two-year follow up of women randomised to medical management or transcervical resection of the endometrium for heavy menstrual loss: clinical and quality of life outcomes. Br J Obstet Gynaecol (1999) 2.16
Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol (1999) 2.13
Early loss of heterozygosity on 17q in ovarian cancer. The Abe Ovarian Cancer Genetics Group. Oncogene (1992) 2.13
Children, stress, and hospitalization: a field experiment. J Health Soc Behav (1968) 2.11
A randomised comparison of medical and hysteroscopic management in women consulting a gynaecologist for treatment of heavy menstrual loss. Br J Obstet Gynaecol (1997) 2.10
Antenatal screening for carriers of cystic fibrosis: randomised trial of stepwise v couple screening. BMJ (1995) 2.06
Randomised trial comparing hysterectomy with endometrial ablation for dysfunctional uterine bleeding: psychiatric and psychosocial aspects. BMJ (1996) 2.00
Assessment of cardiac output by the Doppler ultrasound technique alone. Br Heart J (1985) 1.97
Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet (2005) 1.91
Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer (2010) 1.89
Conductance switching in single molecules through conformational changes. Science (2001) 1.89
Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet (1992) 1.80
Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification. Br J Cancer (2004) 1.77
Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. Br J Cancer (2008) 1.77
Is it reality or an illusion that liquid-based cytology is better than conventional cervical smears? Cytopathology (2002) 1.75
Light chain isotype-associated suppression of normal plasma cell numbers in patients with multiple myeloma: Medical Research Council's Working Party for Leukaemia in Adults and the Oxford Lymphoma Group. Int J Cancer (1979) 1.75
Repeated freezing and thawing of peripheral blood and DNA in suspension: effects on DNA yield and integrity. J Med Genet (1990) 1.74
Carney complex, Peutz-Jeghers syndrome, Cowden disease, and Bannayan-Zonana syndrome share cutaneous and endocrine manifestations, but not genetic loci. J Clin Endocrinol Metab (1998) 1.63
Human papillomavirus testing and the outcome of treatment for cervical intraepithelial neoplasia. Obstet Gynecol (2001) 1.60
Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group. Eur J Cancer (1998) 1.60
Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. J Clin Oncol (1994) 1.58
Aortic blood velocity measurement in healthy adults using a simple ultrasound technique. Cardiovasc Res (1983) 1.58
Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg (1994) 1.57
Age-restricted cervical screening: HPV testing at age 50 identifies a high risk group for cervical disease. Int J Gynecol Cancer (2002) 1.55
Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb Haemost (2002) 1.52
Small-cell lung cancer after retinoblastoma. Lancet (1989) 1.48
Chromosomal aberration and sister-chromatid exchange frequencies in peripheral blood lymphocytes of a large human population sample. II. Extension of age range. Mutat Res (1989) 1.46
A population-based study of microinvasive disease of the cervix--a colposcopic and cytologic analysis. Gynecol Oncol (1992) 1.46
Immunoperoxidase staining of surface and intracellular immunoglobulin in human neoplastic lymphoid cells. J Clin Pathol (1980) 1.45
The natural history of low grade non-Hodgkin's lymphoma and the impact of a no initial treatment policy on survival. Q J Med (1991) 1.45
Identification of inguinal lymph node metastases from vulval carcinoma by magnetic resonance imaging: an initial report. Clin Radiol (2002) 1.43
Antigens on human plasma cells identified by monoclonal antibodies. J Immunol (1983) 1.41
Uterine activity during spontaneous labour after previous lower-segment caesarean section. Br J Obstet Gynaecol (1989) 1.38
Normal G2 chromosomal radiosensitivity and cell survival in the cancer family syndrome. Cancer Res (1988) 1.37
Start a DNA diagnostic service. BMJ (1988) 1.29
Tamoxifen as primary treatment of breast cancer in elderly or frail patients: a practical management. Br Med J (Clin Res Ed) (1985) 1.29
Aromatase inhibitors and arthralgia. J Clin Oncol (2001) 1.27
The impact of chemotherapy on small cell carcinoma of the bronchus. Q J Med (1986) 1.26
Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res (2001) 1.26
Comparative genomic hybridization and chromosomal instability in solid tumours. Br J Cancer (1999) 1.24
How far is the cardiac output? Lancet (1984) 1.24
Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer. J Med Genet (2011) 1.23
Information giving in oncology: a preliminary study of tape-recorder use. Br J Clin Psychol (1992) 1.22
Osseous metaplasia of the endometrium treated by hysteroscopic resection. Br J Obstet Gynaecol (1993) 1.21
Polymorphic variation in CYP19 and the risk of breast cancer. Carcinogenesis (2001) 1.19
Allele losses on chromosome 17 in human epithelial ovarian carcinoma. Oncogene (1990) 1.19
Primary systemic therapy for operable breast cancer. Br J Cancer (1991) 1.19
Colposcopy in a family planning clinic: a future model? Br Med J (Clin Res Ed) (1987) 1.12
The case for stopping cervical screening at age 50. Br J Obstet Gynaecol (1997) 1.12
Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). Vaccine (2004) 1.11
Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. Int J Gynecol Cancer (2006) 1.11
HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study. Br J Cancer (2011) 1.10
Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. Br J Cancer (2001) 1.09
Requirement for expert histopathological assessment of ovarian cancer and borderline tumors. Br J Cancer (2000) 1.08
Apoptosis, ageing and cancer susceptibility. Br J Cancer (2003) 1.08
Five-year follow-up of women with borderline and mildly dyskaryotic cervical smears. Cytopathology (2004) 1.08
Efficacy of cervical-smear collection devices: a systematic review and meta-analysis. Lancet (1999) 1.08
Fertility and pregnancy outcome following large loop excision of the cervical transformation zone. Br J Obstet Gynaecol (1995) 1.07
Phase II trial of vindesine and VP16-213 in the palliation of poor-prognosis patients and elderly patients with small cell lung cancer. Cancer Chemother Pharmacol (1984) 1.07
Primary systemic therapy for operable breast cancer--10-year survival data after chemotherapy and hormone therapy. Br J Cancer (1997) 1.07
Mutations in the connexin 32 gene in X-linked dominant Charcot-Marie-Tooth disease (CMTX1) Hum Mol Genet (1994) 1.07
Comparative genomic hybridization analysis of chromosomal alterations induced by the development of resistance to thymidylate synthase inhibitors. Cancer Res (1998) 1.06
Significant telomere shortening in childhood leukemia. Cancer Genet Cytogenet (1992) 1.05
A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations. J Med Genet (2010) 1.04
Method of assessing the reproducibility of blood flow measurement: factors influencing the performance of thermodilution cardiac output computers. Br Heart J (1986) 1.04
Colorectal cancer genomics: evidence for multiple genotypes which influence survival. Br J Cancer (2001) 1.04
Improving the referral process for familial breast cancer genetic counselling: findings of three randomised controlled trials of two interventions. Health Technol Assess (2005) 1.04
Autosomal dominant retinitis pigmentosa (ADRP): a rhodopsin mutation in a Scottish family. J Med Genet (1992) 1.04
Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma. Br J Cancer (1992) 1.03
Dexamethasone and high dose metoclopramide: efficacy in controlling cisplatin induced nausea and vomiting. Br Med J (Clin Res Ed) (1984) 1.03
Rhodopsin mutations in a Scottish retinitis pigmentosa population, including a novel splice site mutation in intron four. Br J Ophthalmol (1994) 1.02
Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? BMJ (1991) 1.02
Mild and moderate dyskaryosis: can women be selected for colposcopy on the basis of social criteria? BMJ (1992) 1.02
Mammographic surveillance in women aged 35-39 at enhanced familial risk of breast cancer (FH02). Fam Cancer (2014) 1.02
Paget's disease of bone: evidence for a susceptibility locus on chromosome 18q and for genetic heterogeneity. J Bone Miner Res (1998) 1.02
Prevalence of cystic fibrosis mutations in the Grampian region of Scotland. J Med Genet (1993) 1.02
Effects of oestrogen on the expression of a 4.4 kb mRNA in the ZR-75-1 human breast cancer cell line. Mol Cell Endocrinol (1988) 1.02
Paradoxical embolism. A review of cases diagnosed during life. Eur Heart J (1982) 1.01
Epidermal growth factor (EGF) increases the in vitro invasion, motility and adhesion interactions of the primary renal carcinoma cell line, A704. Eur J Cancer (1996) 1.01
Folate and breast cancer: the role of polymorphisms in methylenetetrahydrofolate reductase (MTHFR). Cancer Lett (2002) 1.00
A 10-year experience of tamoxifen as primary treatment of breast cancer in 100 elderly and frail patients. Eur J Surg Oncol (1991) 1.00
Biological and hormonal markers of chlamydia, human papillomavirus, and bacterial vaginosis among adolescents attending genitourinary medicine clinics. Sex Transm Infect (2005) 0.99
Genotype-phenotype correlations of new causative APC gene mutations in patients with familial adenomatous polyposis. J Med Genet (1995) 0.99